Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;41(1):187-194.
doi: 10.1007/s10067-021-05896-0. Epub 2021 Sep 2.

Juvenile Behçet's disease: a tertiary center experience

Affiliations

Juvenile Behçet's disease: a tertiary center experience

Zahide Ekici Tekin et al. Clin Rheumatol. 2022 Jan.

Abstract

Objectives: Juvenile Behçet's disease is a rare and severe disease of childhood characterized by a chronic inflammatory vasculitis. The aim of the present study is reporting demographic, clinical and therapeutic outcomes of juvenile Behçet's disease in a tertiary center.

Methods: The retrospective study included patients who were diagnosed Behçet's disease before 16 years. The demographic and clinical features, and diagnostic and therapeutic strategies of patients were recorded.

Results: Seventy-two patients with jBD were included in this study; 32 were male (44.4%). Thirty (41.7%) patients had BD cases in their family. We observed oral ulceration (100%), genital ulceration (68.1%), joint involvement (36.1%) and cutaneous manifestations (34.7%) as the most common clinical findings, respectively. As severe organ involvements, 20.8% ocular, 18.1% vascular and 15.3% neurologic pathologies were seen. All patients had colchicine. Corticosteroid (20.8%) was used to treat severe cases and acute attacks. Azathioprine (23.6%) was the main immunosuppressive agent and cyclophosphamide (8.3%) was applied initially for life-threatening conditions with pulse methylprednisolone.

Conclusion: In this cohort, the prevalence of genital ulceration and family history was high, and we observed less ocular involvement, a few permanent neurological morbidities and no death. Key Points • In the present study, there were acceptable permanent neurological involvements as morbidity and no mortality. • It is important noticing and managing jBD in early phase in order to prevent the devastating results. • The awareness of jBD provides timely treatment of patients. • The positivity of family history and HLA B51 should alert the clinician about the incomplete cases.

Keywords: Behçet’s disease; Children; Clinical features; Treatment; Vasculitis.

PubMed Disclaimer

References

    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11 - DOI
    1. Ozen S (2010) Pediatric onset Behçet disease. Curr Opin Rheumatol 22:585–589 - DOI
    1. Yildiz M, Koker O, Adrovic A, Sahin S, Barut K, Kasapcopur O (2019) Pediatric Behçet’s disease - clinical aspects and current concepts. Eur J Rheumatol 7:1–10
    1. Kone-Paut I (2016) Behcet’s disease in children, an overview. Pediatr Rheumatol. 14:10. https://doi.org/10.1186/s12969-016-0070-z - DOI
    1. Yurdakul S, Hamuryudan V, Yazici H (2004) Behçet syndrome. Curr Opin Rheumatol 16:38–42. https://doi.org/10.1097/00002281-200401000-00008 - DOI - PubMed

LinkOut - more resources